HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics].

AuthorsRoxane Meurillon, Amaury Leruste
JournalBulletin du cancer (Bull Cancer) Vol. 110 Issue 3 Pg. 250-251 (03 2023) ISSN: 1769-6917 [Electronic] France
Vernacular TitleNouvelle AMM : crizotinib dans le lymphome anaplasique à grandes cellules systémique ALK positif en pédiatrie.
PMID36754658 (Publication Type: Letter)
Chemical References
  • Crizotinib
  • Receptor Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors
  • Antineoplastic Agents
Topics
  • Child
  • Humans
  • Crizotinib (therapeutic use)
  • Lymphoma, Large-Cell, Anaplastic (drug therapy)
  • Drug Approval
  • Receptor Protein-Tyrosine Kinases
  • Pediatrics
  • Protein Kinase Inhibitors (therapeutic use)
  • Lung Neoplasms
  • Antineoplastic Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: